Clinical Trial Update: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy [Phase 1, Phase 2]

View source ↗

Summary

The QUILT-3.051 trial evaluating the NANT Ovarian Cancer Vaccine in epithelial ovarian cancer has been withdrawn in subjects who progressed on or after standard…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• NANT Ovarian Cancer Vaccine

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: WITHDRAWN